B I Hirschowitz

Summary

Affiliation: University of Alabama at Birmingham
Country: USA

Publications

  1. ncbi Absence of gastrointestinal infections in a cohort of patients with Zollinger-Ellison syndrome and other acid hypersecretors receiving long-term acid suppression with lansoprazole
    C Mel Wilcox
    Department of Medicine, Division of Gastroenterology and Hepatology, University of Alabama at Birmingham, Birmingham, Alabama, USA
    BMC Gastroenterol 8:18. 2008
  2. ncbi Usual and unusual causes of duodenal ulcer
    B I Hirschowitz
    Division of Gastroenterology and Hepatology, Department of Medicine, University of Alabama at Birmingham, Birmingham, AL 35294, USA
    Dig Liver Dis 35:519-22. 2003
  3. ncbi Clinical outcome using lansoprazole in acid hypersecretors with and without Zollinger-Ellison syndrome: a 13-year prospective study
    Basil I Hirschowitz
    Division of Gastroenterology and Hepatology, The University of Alabama at Birmingham, UAB Station, Birmingham, AL 35294 0007, USA
    Clin Gastroenterol Hepatol 3:39-48. 2005
  4. ncbi Risk factors for esophagitis in extreme acid hypersecretors with and without Zollinger-Ellison syndrome
    Basil I Hirschowitz
    Division of Gastroeneterology and Hepatology, University of Alabama at Birmingham, Alabama, USA
    Clin Gastroenterol Hepatol 2:220-9. 2004
  5. ncbi Vitamin B12 deficiency in hypersecretors during long-term acid suppression with proton pump inhibitors
    B I Hirschowitz
    Division of Gastroenterology and Hepatology, University of Alabama School of Medicine, Birmingham, AL 35294, USA
    Aliment Pharmacol Ther 27:1110-21. 2008
  6. ncbi Chromogranin A in patients with acid hypersecretion and/or hypergastrinaemia
    B I Hirschowitz
    The University of Alabama at Birmingham, Division of Gastroenterology and Hepatology, University Station, Birmingham, AL 35294 0007, USA
    Aliment Pharmacol Ther 26:869-78. 2007
  7. ncbi Long-term lansoprazole control of gastric acid and pepsin secretion in ZE and non-ZE hypersecretors: a prospective 10-year study
    B I Hirschowitz
    The University of Alabama at Birmingham, Division of Gastroenterology and Hepatology, University Station, Birmingham, AL, USA
    Aliment Pharmacol Ther 15:1795-806. 2001
  8. ncbi Helicobacter pylori effects on gastritis, gastrin and enterochromaffin-like cells in Zollinger-Ellison syndrome and non-Zollinger-Ellison syndrome acid hypersecretors treated long-term with lansoprazole
    B I Hirschowitz
    Division of Gastroenterology and Hepatology, The University of Alabama at Birmingham, 35294, USA
    Aliment Pharmacol Ther 15:87-103. 2001
  9. ncbi Minor effects of Helicobacter pylori on gastric secretion and dose of lansoprazole during long-term treatment in ZE and non-ZE acid hypersecretors
    B I Hirschowitz
    Division of Gastroenterology and Hepatology, The University of Alabama at Birmingham, UAB Station, Birmingham, AL 35294 0007, USA
    Aliment Pharmacol Ther 16:303-13. 2002
  10. ncbi Pepsin and the esophagus
    B I Hirschowitz
    Division of Gastroenterology and Hepatology, University of Alabama at Birmingham, 35294 0007, USA
    Yale J Biol Med 72:133-43. 1999

Collaborators

Detail Information

Publications17

  1. ncbi Absence of gastrointestinal infections in a cohort of patients with Zollinger-Ellison syndrome and other acid hypersecretors receiving long-term acid suppression with lansoprazole
    C Mel Wilcox
    Department of Medicine, Division of Gastroenterology and Hepatology, University of Alabama at Birmingham, Birmingham, Alabama, USA
    BMC Gastroenterol 8:18. 2008
    ..The relationship between proton pump inhibitor therapy and other acid suppressing medications and the risk of gastrointestinal infections remains controversial...
  2. ncbi Usual and unusual causes of duodenal ulcer
    B I Hirschowitz
    Division of Gastroenterology and Hepatology, Department of Medicine, University of Alabama at Birmingham, Birmingham, AL 35294, USA
    Dig Liver Dis 35:519-22. 2003
  3. ncbi Clinical outcome using lansoprazole in acid hypersecretors with and without Zollinger-Ellison syndrome: a 13-year prospective study
    Basil I Hirschowitz
    Division of Gastroenterology and Hepatology, The University of Alabama at Birmingham, UAB Station, Birmingham, AL 35294 0007, USA
    Clin Gastroenterol Hepatol 3:39-48. 2005
    ..The aims of this study were to heal and prevent relapse of acid/peptic lesions during acid suppression and to analyze benefits and risks during long-term lansoprazole treatment...
  4. ncbi Risk factors for esophagitis in extreme acid hypersecretors with and without Zollinger-Ellison syndrome
    Basil I Hirschowitz
    Division of Gastroeneterology and Hepatology, University of Alabama at Birmingham, Alabama, USA
    Clin Gastroenterol Hepatol 2:220-9. 2004
    ..We quantified the incidence of esophagitis and various risk factors that might contribute to it...
  5. ncbi Vitamin B12 deficiency in hypersecretors during long-term acid suppression with proton pump inhibitors
    B I Hirschowitz
    Division of Gastroenterology and Hepatology, University of Alabama School of Medicine, Birmingham, AL 35294, USA
    Aliment Pharmacol Ther 27:1110-21. 2008
    ..However, B12 deficiency elevates methylmalonic acid and homocysteine, both additional markers of B12 deficiency...
  6. ncbi Chromogranin A in patients with acid hypersecretion and/or hypergastrinaemia
    B I Hirschowitz
    The University of Alabama at Birmingham, Division of Gastroenterology and Hepatology, University Station, Birmingham, AL 35294 0007, USA
    Aliment Pharmacol Ther 26:869-78. 2007
    ..Chromogranin has been proposed as a marker for gastrin-dependent enterochromaffin-like cell proliferation...
  7. ncbi Long-term lansoprazole control of gastric acid and pepsin secretion in ZE and non-ZE hypersecretors: a prospective 10-year study
    B I Hirschowitz
    The University of Alabama at Birmingham, Division of Gastroenterology and Hepatology, University Station, Birmingham, AL, USA
    Aliment Pharmacol Ther 15:1795-806. 2001
    ..The majority of patients with Zollinger-Ellison syndrome require lifelong treatment with proton pump inhibitors...
  8. ncbi Helicobacter pylori effects on gastritis, gastrin and enterochromaffin-like cells in Zollinger-Ellison syndrome and non-Zollinger-Ellison syndrome acid hypersecretors treated long-term with lansoprazole
    B I Hirschowitz
    Division of Gastroenterology and Hepatology, The University of Alabama at Birmingham, 35294, USA
    Aliment Pharmacol Ther 15:87-103. 2001
    ..Helicobacter pylori is said to cause atrophy of the gastric corpus and enterochromaffin-like cell proliferation in gastro-oesophageal reflux disease (GERD) patients treated long-term with a proton pump inhibitor...
  9. ncbi Minor effects of Helicobacter pylori on gastric secretion and dose of lansoprazole during long-term treatment in ZE and non-ZE acid hypersecretors
    B I Hirschowitz
    Division of Gastroenterology and Hepatology, The University of Alabama at Birmingham, UAB Station, Birmingham, AL 35294 0007, USA
    Aliment Pharmacol Ther 16:303-13. 2002
    ..Pepsin effects have not been reported. In Zollinger-Ellison syndrome (ZE) specifically, H. pylori has been reported to decrease acid...
  10. ncbi Pepsin and the esophagus
    B I Hirschowitz
    Division of Gastroenterology and Hepatology, University of Alabama at Birmingham, 35294 0007, USA
    Yale J Biol Med 72:133-43. 1999
    ..e., higher than pH 3.5, pepsin does not damage the esophagus. The damage caused by acidified pepsin may be made much worse by the further addition of aspirin or other NSAIDs, presumably by further breaking down mucosal barriers...
  11. ncbi Management of refractory and complicated reflux esophagitis
    B I Hirschowitz
    Department of Medicine, University of Alabama at Birmingham 35294, USA
    Yale J Biol Med 69:271-81. 1996
    ..Dysplasia leading to adenocarcinoma is a different problem, apparently not influenced by reduced exposure to acid. Indications for antireflux surgery are quite limited and should be carefully analyzed as a cost/risk/benefit problem...
  12. ncbi Treatment strategies for Zollinger-Ellison syndrome
    C Mel Wilcox
    Division of Gastroenterology and Hepatology, Department of Medicine, University of Alabama at Birmingham, Birmingham, Alabama 35294 0007, USA
    Expert Opin Pharmacother 10:1145-57. 2009
    ..Until the development of H(2)-receptor antagonists and later proton pump inhibitors (PPIs), the disease was virulent, often associated with ulcer-related mortality, and the mainstay of treatment was total gastrectomy...
  13. ncbi Costs and risks in the management of patients with gastric acid hypersecretion
    Basil I Hirschowitz
    Department of Medicine, Division of Gastroenterology and Hepatology, University of Alabama at Birmingham, Birmingham, AL 35294 0007, USA
    J Clin Gastroenterol 44:28-33. 2010
    ..To define both risks and costs of optimal care of patients with gastric acid hypersecretion...
  14. ncbi Atypical and aggressive upper gastrointestinal ulceration associated with aspirin abuse
    Basil I Hirschowitz
    Division of Gastroenterology and Hepatology, University of Alabama at Birmingham, UAB Station, Birmingham, AL 35294 0007, USA
    J Clin Gastroenterol 34:523-8. 2002
    ..Although some ulcers were caused by Zollinger-Ellison syndrome (ZES), an atypical clinical course in other patients, especially with those with multiple ulcers, suggested abuse of aspirin...
  15. ncbi Clinical aspects of ECL-cell abnormalities
    B I Hirschowitz
    Division of Gastroenterology and Hepatology, University of Alabama at Birmingham 35294-0007, USA
    Yale J Biol Med 71:303-10. 1998
    ..By contrast, single, large, non-gastrin-dependent carcinoids represent a different biological and clinical problem and are frequently malignant...
  16. ncbi Medical management of esophageal reflux
    B I Hirschowitz
    Department of Medicine, School of Medicine, University of Alabama at Birmingham 35294-0007, USA
    Yale J Biol Med 67:223-31. 1994
    ..The essence of effective medical treatment of esophagitis is to reduce acidity of the refluxate to a level outside the optimum proteolytic pH range of pepsin, i.e. greater than pH 3.5...
  17. ncbi Comparison of 13C- urea blood test to 13C-breath test and rapid urease test for the diagnosis of Helicobacter pylori infection
    Lucia C Fry
    Division of Gastroenterology and Hepatology, University of Alabama, Birmingham, USA
    Acta Gastroenterol Latinoam 35:225-9. 2005
    ..We conclude that the 13C urea blood test is highly sensitive and specific for the initial diagnosis and control of eradication of H. pylori infection...